LivaNova (LIVN) Q4 2016 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2016 earnings summary
10 Nov, 2026Executive summary
FY16 net sales were $1,213.9M; operating loss was $93.6M and net loss was $194.6M, including $148.8M of exceptional items and $37.5M of 3T Heater-Cooler remediation expense.
Operational priorities included post-merger integration, restructuring, new product launches, inventory optimization and investment focused on higher-growth areas.
Adjusted earnings reached the high end of guidance; management emphasized future revenue, earnings-per-share and operating-margin growth.
Financial highlights
FY16 revenue was $1,213.9M; gross profit was $695.6M, operating profit before exceptional items was $55.2M, and operating loss was $93.6M.
Net loss attributable to owners was $194.6M; basic and diluted loss per share were both $3.98.
Exceptional items totaled $148.8M: $55.9M restructuring, $20.5M merger and integration, and $72.3M CRM impairment.
A separate $37.5M product-remediation expense related to 3T Heater-Cooler devices was recorded in cost of sales.
FY16 results include Sorin for the full year, unlike the 25 Apr–31 Dec 2015 transitional period; the periods are not comparable.
Outlook and guidance
Management planned to expand operating margins and grow revenue and EPS, supported by product innovation, organic investment and selective external investments.
Existing cash, cash equivalents and expected operating cash generation were considered sufficient for operating needs, working capital, R&D, capital expenditure and debt service over the next 12 months.
Costa Rica manufacturing exit was expected to finish in H1 2017; the broader 2015–16 reorganization plans were expected to conclude in H1 2018.
After year-end, plans were announced to sell the Suzhou facility; the remaining Caisson acquisition was completed in May 2017 for up to $72M, net of $6M debt forgiveness.
Latest events from LivaNova
- Capacity, innovation and reimbursement milestones underpin growth opportunities through 2028.LIVN
Stifel 2026 Healthcare Conference 2026 - Balanced growth supports 2027 expansion across cardiopulmonary, epilepsy and sleep apnea.LIVN
8th Annual Wolfe Research Healthcare Conference - Merger-year sales reached $415.7m, but $72.2m of exceptional costs drove a $29.1m net loss.LIVN
Q4 2015 - COVID-19 pressure and major one-time charges deepened losses as ACS growth offset part of the decline.LIVN
Q4 2020 - Sales and cash generation recovered, but major litigation and clinical execution remain pivotal.LIVN
Q4 2021 - Core segments grew, but ACS impairment and weaker ECMO demand drove a difficult year.LIVN
Q4 2022 - Double-digit 2023 growth supports 2024 guidance amid the ACS wind down.LIVN
Q4 2023 - VNS momentum and supply expansion support growth as OSA advances toward a 2030 target.LIVN
UBS Global Healthcare Conference - Q3 growth lifted FY26 guidance as oxygenator capacity expanded and OSA investment advanced.LIVN
Q3 2026